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ㅋ
Irritable bowel syndrome (IBS) is a common chronic disorder seen in gastroenterology and primary care practice. It is charac-
terized by recurrent abdominal pain or discomfort associated with disturbed bowel function. It is a heterogeneous disorder 
with varying treatments, and in this regard physicians sometimes struggle with finding the optimal approach to management 
of patients with IBS. This disorder induces high health care costs and variably reduces health-related quality of life. IBS is in 
the class of functional gastrointestinal disorders, and results from dysregulation of central and enteric nervous system 
interactions. Psychosocial factors are closely related to their gut physiology, associated cognitions, symptom manifestations and 
illness behavior. Therefore, it is important for the physician to recognize the psychosocial issues of patients with IBS and in 
addition to build a good patient-physician relationship in order to optimize treatment. This review focuses on the interaction 
between psychological and physiological factors associated with IBS by using a biopsychosocial model. In this article, we de-
scribe (1) the predisposing psychological features seen in early life; (2) the psychological factors associated with life stress, the 
symptom presentation, and their associated coping patterns; (3) gut pathophysiology with emphasis on disturbances in mo-
tility, visceral hypersensitivity and brain-gut interactions; and finally (4) the clinical outcomes and effective treatments including 
psychotherapeutic methods.
(J Neurogastroenterol Motil 2011;17:131-139)
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Introduction
Irritable bowel syndrome (IBS) is a part of the larger group 
of functional gastrointestinal disorders (FGIDs), which have dif-
ferent bodily locations and symptom patterns, but which share 
disturbances in the regulation of peripheral, spinal and central 
pathways that are incompletely understood.
1 IBS patients suffer 
from a chronic gastrointestinal (GI) disorder characterized by re-
current abdominal pain associated with altered bowel habits with-
out obvious structural abnormalities seen on endoscopy or 
X-ray.
2,3 The prevalence is high, affecting up to 20% of adults.
4 
When moderate to severe in intensity, patients struggle with se-
vere pain or discomfort, abnormal bowel habit, impaired 
health-related quality of life (HRQOL) and disability.
5 This can 
lead to high work absenteeism, physician visits and health care 
costs.
6,7
Although highly prevalent in society, patients with IBS may Yukari Tanaka, et al
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Table 1. Biopsychosocial Model and Treatment of Irritable Bowel 
Syndrome
Biopsychosocial Model
Early life
Genetic factors
Social learning
Psychosocial factors
Life stress
Abuse history
Psychological state
Anxiety disorder
Panic disorder
Personality
Physiology
Abnormal motility and sensitivity
Brain-gut interaction
Regional brain activation
Hypothalamic-pituitary-adrenal axis
Postinfectious IBS
Treatment
Psychopharmacology
Tricyclic antidepressants 
Selective serotonin reuptake inhibitors 
Noradrenergic and specific serotonergic antidepressant 
Benzodiazepines
Psychotherapies
Cognitive behavioral therapy 
Dynamic psychotherapy
Hypnotherapy
not always receive optimal treatment. Physicians, including gas-
troenterologists, may feel unsure as to how to manage conditions 
without clear structural findings, since this is how traditionally 
physicians are trained. They may perceive this as “illness” without 
“disease.” Furthermore, they may not fully understand the multi-
plicity of factors operative in understanding the pathophysiology 
which adheres to a brain-gut biopsychosocial model. As such, this 
disorder can be associated with major psychosocial distress that 
some physicians may feel ill equipped to manage. Early life expe-
riences including major loss abuse and psychosocial trauma, 
family influences on illness behavior and maladaptive coping 
life-styles can influence the clinical expression and severity of 
IBS. These factors also produce complex interactions that affect 
biological, psychological and social systems for the individual 
with IBS. Thus abdominal symptoms as presented by IBS pa-
tients are only a part of the full understanding of full syndrome, 
perhaps an “alarm sign” of a complex of biopsychosocial factors.
In recent years scientific investigations have brought a great-
er understanding of the pathophysiological processes leading to 
the symptom complex of IBS and in the process have made these 
disorders clinically legitimate. The data have also led to improved 
clinical care and increased public awareness. This report provides 
a better understanding of these newly understood biopsychosocial 
determinants as part of an up-to-date synthesis of current re-
search (Table 1).
Biopsychosocial Model
More recent scientific studies link the mind and the body as a 
part of a system where their dysregulation can produce illness. 
The term “bio-psycho-social” does not mean merely that psycho-
social issues are important, or that psychosocial factors cause 
medical illness (psychogenic and psychosomatic), or that psycho-
logical symptoms result from a medical disorder (somatopsychic 
or psychologic overlay), or even that stress has physiologic effects 
(psychophysiologic), although all may be considered as plausible 
situations subsumed by the model.
8-10
The biopsychosocial model of illness and disease, as de-
scribed by Engel,
8,10,11 has helped understanding the bi-direc-
tional relationship between mind and body and reconcileed the 
dualistic concepts that separated illness and disease. Figure illus-
trates this biopsychosocial understanding of the relationship be-
tween psychosocial and physiological factors associated with 
functional GI symptoms and the clinical outcome.
12 
Early Life
The natural history of symptoms and risk factors that con-
tribute to IBS may begin in early life. Familial studies of IBS 
have demonstrated that reporting a first-degree relative with ab-
dominal pain or bowel problems is significantly associated with 
reporting of IBS symptoms,
13 suggesting a strong environmental 
basis for IBS. Heredity may explain the findings that IBS tends 
to run in families. Both the Australian twins study
14 and the larg-
er US study
15 showed concordance rate for IBS between mono-
zygotic twins was significantly higher than that between dizygotic 
twins. Genetic factors which may be associated with FGIDs may 
include serotonin transporter,
16 IL-10
17 and other genetic 
polymorphisms. Parental attitudes may also be important to the 
development or clinical expression of IBS. Levy et al
15,18 in-
dicated that children of patients with IBS had significantly more 
health care visits than those without IBS.
19,20 Children whose 
mothers have IBS are prone to having more non-GI symptoms as 
well as GI symptoms. This may imply that parents tend to pay at-Biopsychosocial Model of IBS
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Figure. A biopsychosocial conceptuali-
zation of the pathogenesis and clinical 
expression of irritable bowel syndrome 
(IBS). It shows the relationships bet-
ween psychosocial and physiological fac-
tors, IBS symptoms and clinical out-
come. CNS, central nervous system; 
ENS, enteric nervous system; FGID, 
functional gastrointestinal disorder. MD,
medical doctor. Adapted from Dro-
ssman.
12
tention to trivial symptoms, sometimes referred to as “illness be-
havior”.
21 Trained parents who do not pay attention to their chil-
dren’s complaints produce fewer chronic functional abdominal 
symptoms than the parents who do show attention.
22 Thus both a 
genetic and a social learning may contribute to the intergenera-
tional transmission of IBS.
Psychosocial Factors
Life stress
Childhood experiences can affect psychological tendencies. 
As a child’s transition into adulthood, genetics, early learning, 
custom and other environmental influences are integrated into 
each unique personality and behavior. They influence the deter-
mination of stress levels and their ability to cope with them. 
Chronic life stress includes divorce, relationship difficulties, seri-
ous illness (of self or other), lawsuits, business failures, housing 
difficulties and forced redundancies. One’s perception of control 
over stressful unresolved life events, sensation-seeking status and 
degree of psychosocial assets may all mediate the impact of life 
stress.
23
Young children, who suppress the feelings of anger and re-
sentment, may also become conditioned to report somatic symp-
toms when distressed. They cannot recognize or communicate 
the association of symptoms with the stressful antecedents, be-
cause these antecedents are not acknowledged or attended to 
within the family.
24 This can lead to higher pain scores, more 
physician visits, and poorer functioning.
A history of physical or sexual abuse also strongly influences 
the severity of the symptoms with poorer daily function, greater 
psychological distress, and poorer outcome.
25 When compared 
with patients without abuse history, GI clinic patients who have a 
history of abuse reported more severe pain and greater psycho-
logical distress. They spent more days in bed in the previous 3 
months with poorer health status, more often visits to physician in 
GI referral centers and more surgical procedures.
25,26 A history of 
abuse is not always volunteered by patients. In fact, in 1 study on-
ly 17% of the abuse victims had informed their physicians, and 
30% of the victims had not previously disclosed this history to 
anyone.
27 The findings suggest that physicians should become 
aware of many risk factors among patients with chronic or severe 
refractory symptoms.
Psychological state
IBS symptoms are sometimes exacerbated by stress and can 
be associated with psychological co-morbidities. In patients with 
IBS, the most common comorbid psychiatric disorders seen in-
clude anxiety disorders (panic and generalized anxiety disorder), 
depression (including dysthymia), somatoform disorders (hypo-
chondriasis and somatization disorder) and phobic disorders.
28,29 
Psychological distress also affects the somatic symptoms and its 
outcome; it lowers the pain threshold
30,31 and influences health Yukari Tanaka, et al
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care seeking for patients with somatic symptoms.
32 Psychological 
co-morbidities are seen between 42% and 61% of those patients 
with medical disorders and its presence often amplifies or modu-
lates the clinical presentation and outcome.
28,33 Psychosocial diffi-
culties may not be recognized by the patient, and this pattern may 
develop early in life.
34,35
Other psychiatric disturbance and personality (trait anger re-
activity, neuroticism, extroversion and general hypochondriasis) 
were strongly related to the patient’s behavior and overall severity 
of functional gut disturbance.
36 An abuse history relates to its ad-
verse clinical consequences. They include Axis I and Axis II psy-
chiatric diagnoses of posttraumatic stress disorder, dissociation 
disorder and major depression with Axis II disorder of borderline 
personality disorder.
8 Those can be associated with altered GI 
physiology. Drossman et al
28 reported a high frequency of sexual 
and physical abuse history, 44% among women seen at a uni-
versity-based gastroenterology practice. 
Catastrophizing, which has been defined as a cognitive varia-
ble associated with exaggerated intestinal pain, emotional dis-
tress, a morbid pessimism about the condition, perceived help-
lessness and functional limitations,
37,38 is also associated with 
more difficult interpersonal relationships, and can contribute to 
greater worry and suffering in patients with IBS.
39 The ability to 
become consciously aware of one’s own feelings is believed to be a 
cognitive skill requiring certain developmental processes. Ineffective 
coping patterns, such as abdominal pain and discomfort, some-
times particularly induce to catastrophize. Changed cognitions 
with impaired memory and intrusive thoughts, hypervigilance to 
bodily sensations, feelings of ineffectiveness and vulnerability and 
lack of trust finally alter physiological and even structural effects 
on the brain. Recent brain imaging studies have shown that there 
are morphological
40 and functional changes in brain imaging 
among individuals with abuse history.
41 The flashbacks and in-
trusive traumatic memories seen in abuse victims may result from 
stress-mediated alterations in noradrenergic neurons projects to 
the hippocampus, the brain area involved with the encoding and 
retrieval of memory.
36,42 Therefore, consistent with the biopsy-
chosocial model, psychosocial trauma may lead both to physio-
logical and even anatomic alterations.
The above features also interfere with the patient’s ability to 
interact with family, peer groups, and physicians, or to engage in 
a treatment plan. It is important for physicians to recognize these 
maladaptive patterns and maintain clear boundaries of medical 
care. They may refer to clinical skills in the mental health pro-
fessional, when feeling the need of particular specific interviewing 
skills or to assess multiple complex variables.
43 Psychological dis-
tress in IBS patients can usually be reduced with appropriate 
treatment, whereas patients with IBS who have more marked per-
sonality features are much less amenable to treatment.
42 However, 
there is no personality profile unique to IBS.
28,32
Physiology
Abnormal motility and sensitivity 
Patients with IBS show abnormal GI motility and visceral 
hypersensitivity. Colonic segmental contractions and activity are 
exaggerated during stress in IBS patients.
44 IBS patients are also 
likely to indicate lower pain thresholds to balloon distention of the 
colon compared with healthy controls.
45 Recent studies may ex-
plain the physiological abnormalities observed in IBS. A number 
of enterochromaffin  cells which contain serotonin in the gut mu-
cosa are more increasing in patients with IBS than controls.
46 IBS 
patients demonstrated that mast cell proximity to enteric sensory 
nerves correlated with the severity and frequency of abdominal 
pain or discomfort.
47,48 
Brain-gut interaction
As the physiological abnormalities in IBS are closely corre-
lated with psychological stress, the combined functioning of GI 
intestinal motor, sensory and CNS activity is thought to be an im-
portant factor on development of IBS symptoms, which is termed 
as the brain-gut interactions.
49 The brain-gut axis is a bidirec-
tional and integrated system in which thoughts, feelings, memo-
ries and environmental influences can lead to neurotransmitter 
release that affects sensory, motor, endocrine, autonomic, im-
mune and inflammatory function.
50,51 In IBS patients, it may re-
sult from dysregulation of central and enteric nervous system, 
which induces the dysmotility or visceral sensitivity, and is modi-
fied by psychosocial processes. In the end, they determine the ex-
perience of the illness.
52 Therefore, the concepts of the brain-gut 
interactions help us to understand pathophysiology of IBS.
Psychological distress is generated by a network comprised of 
integrative brain structures, in particular, subregions of the hypo-
thalamus, amygdala, and medial thalamus and anterior cingulate 
cortex. They form an integral part of the limbic system, which is 
regarded as the “visceral” or “emotional” brain.
53-55 In the limbic 
system and the cerebral cortex, there are a lot of histamine H1 
binding sites.
56 The H1 receptor blockage induced shortening of 
cerebral evoked potential latencies after electrical painful stim-
ulation of the rectum, suggesting that the brain histamine or its 
receptors may play an important role for nociceptive process in 
the brain.
57 Stress-induced damage to the hippocampus resulted Biopsychosocial Model of IBS
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in long-lived hyperactivity of corticotropin-releasing hormone 
(CRH). CRH is also an important factor on central responses to 
stressful situations.
58 CRH is distributed in the whole brain with 
dense localization in the paraventricular nucleus of the hypo-
thalamus.
59 CRH stimulates pituitary ACTH secretion, which 
releases glucocorticoids from the adrenal glands. It has been re-
ported that CRH aggravated visceral sensorimotor function as 
well as ACTH response in patients with IBS.
58 Increased hypo-
thalamic-pituitary-adrenal responsiveness to stress produces the 
glucocorticoids, which in turn, increase the expression of in-
flammation and induce the production of cytokines.
Postinfectious IBS (PI-IBS) model may be a good example 
of brain and gut interaction. Psychological factors may partly ex-
plain the increased reports of PI-IBS,
60-62 a condition in which at 
least a subgroup of IBS patients reported onset of their IBS 
symptoms after a resolution of acute GI infection. Prospective 
studies have found that anxiety and depression are significant and 
independent risk factors of PI-IBS.
42,60,61,63 However, visceral 
sensation thresholds or motility were not different between 
PI-IBS and those who recover from infection without developing 
IBS.
64-66 These support a better understanding of brain-gut in-
teraction to relate to PI-IBS, with visceral sensitization and high 
levels of psychological distress.
Outcome
IBS status shows an aspect of illness. “Illness” is defined as 
the personal experience of the medical condition, which is evident 
from the person’s symptom reports, perceptions, and behavior. 
“Disease” is abnormalities in the structure and function of organs 
and tissues. It is externally verifiable by evidence from a patho-
logical state. Illness can be inappropriately dichotomized to a dis-
ease, or organic disorder, which presumably distinguish medical 
(organic) from psychological (functional) illness or relegates 
functional illness to a condition with no cause or treatment.
8
Appropriate coping and social supports may manage the ef-
fects of life stress, abuse, and morbid psychological factors on the 
illness and its outcome. Coping has been defined as “problem 
solving efforts, both action-oriented and intrapsychic, to manage 
external and internal demands and conflicts that are apprised as 
taxing or exceeding a person’s resources”.
67 In general, emo-
tion-focused coping, although possibly adaptive for acute over-
whelming stresses, is not effective for chronic stressors. Whereas 
problem-focused coping strategies (eg, seeking social support or 
reappraising the stressor) involves efforts by finding out one’s re-
sponse to the stressor and learning skills to manage the problems, 
that is more effective for chronic illness. Social supports through 
family, supportive relationships, social participation and social 
networks can have similar benefits in reducing the impact of 
stressors on physical and mental illness, thereby improving ability 
to cope with the illness.
68 Therefore, IBS patients, who have se-
vere and chronic life threats, may lack of satisfactory inter-
personal support. They also cannot improve the symptom in-
tensity over time and reduce the HRQOL.
28,69
Treatment
To control IBS symptoms, some medications based on the 
pathophysiology are often used. Motility and pain modifying 
medications, such as enteric agents, fiber, prokinetics, are useful, 
in particular, for mild IBS.
70 However, physicians may treat pa-
tients with more severe symptoms whose medications are not 
working as well as hoped. Because psychological factors often ad-
versely affect IBS, psychopharmacological or psychological treat-
ments can be employed to reduce their impact on the GI 
symptoms. Furthermore, good psychosocial treatment must also 
rest on good relationships between physician and patients - the 
patient-physician relationship. 
Approach to the Patient
In the course of caring and evaluating for patients, different 
perspectives between patients and physicians may occur with re-
gard to the role of psychosocial factors in the illness. Certainly 
psychosocial factors may influence symptoms and behaviors in 
ways that are not readily treatable by disease-specific methods.
8 
Some patients, for example those who have experienced severe 
traumatic events such as sexual abuse, may initially be unwilling 
to accept the role of psychosocial factors in the illness. It is im-
portant for the physician to develop an effective patient-physician 
interaction, to improve the therapeutic outcome. This can be es-
tablished with attention to several issues: (1) make an effort to 
understand and offer empathy when patients report the experi-
ence of the illness; (2) obtain the history and acknowledge the 
role of the patient’s psychological factors; (3) clarify any mis-
understandings; (4) provide education how to manage the illness, 
including psychosocial function; and (5) make a plan of treat-
ment with the patient.
29,71
Physicians should also obtain histories about the associations 
between bowel symptoms and psychosocial factors. Obtaining in-
formation that relates the daily pattern of the symptoms to ag-
gravating factors such as the timing of menstruation, dietary or Yukari Tanaka, et al
     
136 Journal of Neurogastroenterology and Motility 
Table 2. Consultation to Mental Health Professionals
Psychiatric disorders 
(eg, major depression and panic disorders)
Other identifiable psychiatric disorders, which require specific
treatments
(eg, antidepressants, CBT and other psychotherapy)
Chronic refractory pain
Severe impairment
Abnormal illness behavior
Difficulties in physician-patient interaction
Idiosyncratic health beliefs
History of abuse or other significant trauma
CBT, cognitive behavioral therapy.
life-style changes and stressors can provide the basis for behav-
ioral modification or even cognitive-behavioral strategies. Thus, 
the therapeutic plan should be individualized and established on 
the relationships between the patient and physician.
It is preferable for gastroenterologists and primary care doc-
tors to work closely with mental health professional, if available. 
In particular, this should occur if the patient shows (1) a severe 
depression, which may be accompanied by suicidal ideas, (2) 
chronic refractory pain, (3) severe disability, (4) maladaptive ill-
ness behavior, (5) difficulties in physician-patient interaction, (6) 
idiosyncratic health beliefs and (7) other identifiable psychiatric 
difficulties (somatization disorder, post-traumatic stress disorder 
and severe anxiety), history of abuse that leads to continuing dis-
tress and/or marked distress (Table 2).
28,72
Psychopharmacology
Psychopharmacologic agents work on neurotransmitter re-
ceptors in the brain-gut regulatory pathways that target seroto-
nergic, dopaminergic, opioidergic and noradrenergic receptor 
sites in the brain. Their effects may be to reduce central modu-
lation of visceral afferents, moderate visceral pain, and improve 
underlying psychiatric conditions, such as anxiety, depression, 
nausea, and loss of appetite.
70 Prescribing psychopharmacologic 
agents is best accomplished in the context of a strong physi-
cian-patient relationship, where these agents are complementary 
to an overall multicomponent treatment plan. The physician is re-
quired to explain the possible side effects, and expected benefits 
from the medication and address to ensure consistent treatment at 
an appropriate dose level over a longer period of time (2-3 
months) than change rapidly from one drug to another. The tri-
cyclic antidepressants (TCAs), which block transporters of nor-
epinephrine and serotonin, in relatively low doses can reduce 
chronic pain.
73 Selective serotonin reuptake inhibitors (SSRI) are 
used to reduce anxiety and are particularly helpful for psychiatric 
comorbid conditions, including major depression, panic disorder 
and other high-anxiety conditions.
74 However, SSRIs have little 
antinociceptive agents and their prokinetic effect which produce 
cramping, nausea and diarrhea, the patient with abdominal pain, 
diarrhea or nausea would do well with a TCA. The serotonin- 
norepinephrine reuptake inhibitors and the noradrenergic and 
specific serotonergic antidepressant are relatively new classes of 
antidepressants that have substantial serotonergic and nora-
drenergic effects (unlike the SSRIs) to be particularly helpful for 
the treatment of painful conditions, but without the anti-
histaminic and anticholinergic effects of the TCAs that lead to 
most of the side effects, including dry mouth, difficulty urinating, 
constipation, decrease in sexual ability, nausea, increased heart 
rhythms, migraine, appetite change, and weight gain.
72,75-77
Anxiolytic agents, particularly the benzodiazepines, are effec-
tive for reducing anxiety in the short term, particularly if the anxiety 
is associated with stress induced flare-ups of bowel disturbance.
70 
With considering the long-term basis of CNS depressant effect, 
the potential benefit should be balanced with the long-term risks 
of sedation, drug interactions, habituation and rebound after 
withdrawal.
In order to avoid side effects of these drugs, psychopharma-
cologic medication would be started with low doses and then 
gradually increased. Some side effects often go away after the first 
few weeks of drug medication. Medication should be stopped 
with intolerable side effects. Other strategies may exist to manage 
psychopharmacologic-induced dysfunction, including waiting, 
reducing, use of adjunctive pharmacotherapy, and switching to 
another drugs.
Opiates have little role in treating patients with chronic pain 
or psychosocial disturbance and often induce narcotic bowel 
syndrome. A narcotic help the pain at first, but the progressive 
and paradoxical increase in abdominal pain is followed despite 
continued or escalated dosages of narcotic prescribed in an effort 
to relieve the pain.
30,78 It can be seen in the patient who often visits 
emergency department or the clinical service with no diagnosis or 
meaningful treatment plan and is prescribed with opiates.
71
The placebo response rate in IBS trials is high, which is ap-
proximately 47%,
79 and providing placebo treatment with de-
fined positive physician-patient relationships showed higher clin-
ical outcome.
80 An effective physician-patient relationship would 
help to manage a consistent plan of narcotic withdrawal coupled 
with the initiation of effective alternative treatments to manage Biopsychosocial Model of IBS
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the pain and bowel symptoms.
Psychotherapies
Psychological treatments (eg, cognitive behavioral therapy, 
dynamic psychotherapy and hypnotherapy) are often appropriate 
for IBS patients.
81 Cognitive behavioral therapy helps IBS pa-
tients to learn new ways of thinking and behaving skills for taking 
a more proactive role in controlling symptoms, coping with their 
emotional anxieties, and improving illness beliefs in chronic 
pain.
82,83 Dynamic psychotherapy consists of close relationships 
between the patient and therapist, which induce the patient to 
overcome internal resistance and learn how to respond in such  
relationship.
83 Hypnotherapy, which alters the conscious state, 
requires specialized training to be used in IBS.
57,84 Psychological 
treatments are, as a class of interventions, effective in reducing 
symptoms compared with a pooled group of control conditions.
85 
The most important aspect of treatment is the patient’s accept-
ance of the need for treatment and his or her motivation to engage 
in it. This can be indicated if the gastroenterologist and psycholo-
gist/psychiatrist help the patient to accept the treatment as a nec-
essary part of an overall plan of care.
Conclusion
IBS is often explained as a “functional” disorder, meaning 
the inclusion of both physiological and psychological factors. 
When an IBS patient is first seen, he or she often mainly com-
plains about chronic abdominal symptoms, such as pain, dis-
comfort, and diarrhea. While some physicians may focus primar-
ily on “abdominal” symptoms, from the point of view of biopsy-
chosocial model, stress can play an important part in the full clin-
ical expression and outcome of the disorder. Therefore, physi-
cians should focus on integrating the medical components of the 
illness with the patient’s psychological aspects and try to build a 
more satisfactory treatment on this understanding. 
Using the concept of biopsychosocial model may be a good 
way to explain the interaction between psychological and physio-
logical factors, which may exist in patients with IBS. However, 
research methods of brain and gut, or stress and cognition are 
limited, thus further studies are awaited.
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